Diagnostica Stago Offers Three Factor VII Detection Methods

June 29, 2012, Parsippany, NJ — Diagnostica Stago, Inc. announces products to suit a variety of clinical research needs for factor VII (FVII). Factor VII is a zymogen that, upon activation to its active form factor VIIa (FVIIa), together with Tissue Factor (TF), comprises the first step in the extrinsic pathway of blood coagulation leading to thrombin formation and subsequent formation of the fibrin clot. Fibrin clot formation is critical for normal hemostasis to occur. All the methods below, which utilize citrated plasma, provide researchers with additional tools to investigate FVII biology, structure and function.

Investigations into FVII biology have been performed previously for applications such as investigation into hypercoagulability as a result of hematological neoplasia (1), combined hyperlipidemia (2), cancer associated thrombosis (3) or FVII hyperactivity as a function of age (4). In addition, FVII function has been investigated in hypocoagulable states as a result of underlying conditions such as liver dysfunction (5) along with FVII congenital or acquired deficiency (6-8).

Staclot® VIIa-rTF (catalog #00281) is a kit for plasma analysis of circulating FVIIa using a clotting method. This unique product is a tool for research studies where the determination of FVIIa levels may be useful due to the fact that it reflects coagulation activation as a result of in vivo FVIIa production.

Asserachrom® VII:Ag (catalog #00241) is an enzyme-linked immunosorbent assay (ELISA) that determines the antigen level of factor VII in plasma samples.

Asserachrom® VIIa-AT (catalog #00491) is a new kit for the analysis of plasma circulating factor VIIa-Antithrombin (FVIIa-AT) complex levels by the ELISA method, and can be run on any plate reader reporting absorbance at 450 nm. This first of its kind product is useful for examination of FVIIa-AT levels, which has been recognized in the literature as a surrogate marker for the extent of tissue factor (TF) exposure to plasma as a result of coagulation activation in prothrombotic disease states such as arterial and venous thrombosis. Unlike the FVIIa-TFPI complex, which stays bound to the endothelium, FVIIa-AT is present in the blood upon physiological coagulation activation, making it a useful surrogate marker for this phenomenon.

All three factor VII detection methods described are labeled for research use only (not for use in diagnostic procedures) in the US and Canada.

About Diagnostica Stago, Inc.

Diagnostica Stago, Inc. is the exclusive provider of the Diagnostica Stago Hemostasis product lines in the United States and offers a complete system of coagulation instruments and optimized reagent kits for research as well as for routine analysis. Diagnostica Stago, Inc. is the U.S. subsidiary of Diagnostica Stago, S.A.S. France, a leader in the development and manufacture of Hemostasis products. For more information about any Stago product or service, please call 800-222-COAG or visit our website at www.stago-us.com.

  1. Negaard et al., Thromb Haemost 99, (2008) 1040-1048.
  2. Nordoy et al., Thromb Haemost 1, (2003) 690-697.
  3. Spiezia, et al., Thromb Res (2012) Epub ahead of print.
  4. Mariani, et al., Haematologica 84, (1999) 620-626.
  5. Rodriguez-Inigo, et al., Blood Coagul Fibrinolysis 12, (2001) 193-199.
  6. Tirindelli, et al., Am J Hemat 26, (1987) 313-321.
  7. Delmer, et al., Blood 74, (1989) 229-232.
  8. Spiezia, et al., Thromb Haemost 103, (2010) 1188-1192.